Publikationen von 1989 bis 1999

  • Erdlenbruch B, Jendrossek V, Gerriets A, Vetterlein F, Eibl H, Lakomek M. Erucyl­­phospho­choline: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. Cancer Chemother. Pharmacol., 44, 484-490 (1999).
  • Jendrossek V, Erdlenbruch B, Hunold A, Kugler W, Eibl H, Lakomek M. Erucyl­phos­phocholine, a novel antineoplastic ether lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro. Int. J. Oncol., 14, 15-22 (1999).
  • Erdlenbruch B, Jendrossek V, Marx M, Hunold A, Eibl H, Lakomek M. Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo. Anticancer Res., 18, 2551-2557 (1998).
  • Jendrossek V, Ritzel A, Neubauer B, Heyden S, Gahr M. An in-frame triplet deletion within the gp91-phox gene in an adult X-linked chronic granulomatous disease patient with residual NADPH-oxidase-activity. Europ. J. Haematol., 58, 78-85 (1997).
  • Liese JG, Jendrossek V, Jansson A, Petropoulou T, Kloos S, Gahr M, Belohradsky BH. Chronic granulomatous disease in adults. Lancet, 347, 220-223 (1996).
  • Jendrossek V, Peters AM, Buth S, Liese J, Wintergerst U, Belohradsky BH, Gahr M. Improvement of superoxide production in monocytes from patients with chronic granulomatous disease by recombinant cytokines. Blood, 81, 2131-2136 (1993).
  • Jendrossek V, Damm U, Liese J, Belohradsky BH, Gahr M. Is the IFN-gamma- induced enhancement of superoxide production in CGD-phagocytes caused by increased expression of the p47-phox cytosolic protein? Immunodeficiency, 4, 187-190 (1993).
  • Jendrossek V, Buth S, Stetter C, Gahr M. Modulation of human monocyte superoxide production by recombinant interleukin-3. Agents Actions, 37, 127-133 (1992).
  • Gahr M, Jendrossek V, Peters AM, Tegtmeyer F, Heyne K. Sea blue histiocytes in the bone marrow of variant chronic granulomatous disease with residual monocyte NADPH-oxidase activity. Br. J. Haematol., 78, 278-280 (1991).
  • Gahr M, Jendrossek V, Speer CP: Pathophysiology, diagnosis and therapy of disorders of granulo­cyte function. Review. Monatsschr. Kinderheilkd. 137, 380-389 (1989). (Review).

Nach oben